Bcl-2 Monoclonal Antibody

$25 ug total protein per lane of various lysates (see on figure) probed with Bcl-2 monoclonal antibody, unconjugated (bsm-10846M) at 1:1000 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.$

25 ug total protein per lane of various lysates (see on figure) probed with Bcl-2 monoclonal antibody, unconjugated (bsm-10846M) at 1:1000 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.

$The Hela (H) cells were fixed with 4% PFA (10 min at r.t.) and then permeabilized with 90% ice-cold methanol for 20 min at -20\u2103,the cells then were incubated in 5%BSA to block non-specific protein-protein interactions (30 min at r.t.).Primary Antibody (green):Mouse Anti-Bcl-2 antibody (bsm-10846M): 1 \u03bcg\/10^6 cells; Secondary Antibody (white blue): Goat anti-Mouse IgG-BF488(bs-60296G-BF488): 1 \u03bcg\/test. Blank control (black): PBS. Acquisition of 20,000 events was performed.$

The Hela (H) cells were fixed with 4% PFA (10 min at r.t.) and then permeabilized with 90% ice-cold methanol for 20 min at -20\u2103,the cells then were incubated in 5%BSA to block non-specific protein-protein interactions (30 min at r.t.).Primary Antibody (green):Mouse Anti-Bcl-2 antibody (bsm-10846M): 1 \u03bcg\/10^6 cells; Secondary Antibody (white blue): Goat anti-Mouse IgG-BF488(bs-60296G-BF488): 1 \u03bcg\/test. Blank control (black): PBS. Acquisition of 20,000 events was performed.

$4% Paraformaldehyde-fixed Hela (H) cell; Triton X-100 at r.t. for 20 min; Antibody incubation with (Bcl-2) monoclonal Antibody, unconjugated (bsm-10846M) 1:100, 90 min at 37\u00b0C; followed by conjugated Goat Anti-Mouse IgG antibody (green, bs-60296G-BF488) at 37\u00b0C for 90 min, DAPI (blue, C02-04002) was used to stain the cell nuclei. PBS instead of the primary antibody was used as the blank control.$

4% Paraformaldehyde-fixed Hela (H) cell; Triton X-100 at r.t. for 20 min; Antibody incubation with (Bcl-2) monoclonal Antibody, unconjugated (bsm-10846M) 1:100, 90 min at 37\u00b0C; followed by conjugated Goat Anti-Mouse IgG antibody (green, bs-60296G-BF488) at 37\u00b0C for 90 min, DAPI (blue, C02-04002) was used to stain the cell nuclei. PBS instead of the primary antibody was used as the blank control.

Applications

WB
ICC/IF

Reactivity

Human

Overview
Catalog #	bsm-10846m
Product Name	Bcl-2 Monoclonal Antibody
Applications	WB, ICC/IF
Reactivity	Human
Specifications
Conjugation	Unconjugated
Host	Mouse
Source	Recombinant protein fragment (1-220 amino acids range) of human Bcl-2.
Clonality	Monoclonal
Clone #	1A5
Isotype	IgG
Concentration	1ug/ul
Purification	Purified by Protein G.
Storage Buffer	0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage Condition	Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles.
Target
Gene ID	596
Swiss Prot	P10415
Synonyms	Apoptosis regulator Bcl-2; BCL2
Background	Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. Regulates cell death by controlling the mitochondrial membrane permeability. Appears to function in a feedback loop system with caspases. Inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating factor (APAF-1). May attenuate inflammation by impairing NLRP1-inflammasome activation, hence CASP1 activation and IL1B release
Application Dilution
WB	1:300-5000
ICC/IF	1:50-100